1. >
  2. Investors
  3. >
  4. Regulated Information
  5. >
  6. Press Releases – Reg...

PRESS RELEASES

Found 303 Results
Page 2 of 31

Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer


Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]

04/07/2022


Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million


Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]

04/06/2022


Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022


AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]

03/31/2022


Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors


These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022   Paris (France), March 9, 2022 – 7:00 […]

03/09/2022


Onxeo Announces its Financial Agenda for 2022


Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]

01/13/2022


Onxeo appoints Julien Miara as new interim CEO


Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]

01/03/2022


New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments


These pioneering data were highlighted at the EACR-AstraZeneca Virtual Conference during two dedicated sessions   Paris (France), December 8, 2021 […]

12/08/2021


Onxeo Continues to Strengthen its Board of Directors


Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member   Paris […]

11/23/2021


Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector


Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy […]

10/14/2021


Onxeo Reports its 2021 Half-Yearly Financial Results and Provides an Update on its Activities


Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]

07/29/2021


Page 2 of 31